Simultaneous presence of cAMP and cGMP exert a co-ordinated inhibitory effect on the agonist-evoked Ca2+ signal in pancreatic acinar cells.
The stimulation of the pancreatic acinar cells by physiological secretagogues, such as acetycholine (ACh), activates a well-established intracellular signalling pathway, which involves the generation of Inositol 1,4,5-trisphosphate (InsP3) and the release of Ca2+ from intracellular stores. Caffeine, which inhibits this agonist-evoked Ca2+ response reversibly and competitively also blocks the Ca2+ signal generated by the non-specific activation of the membrane guanine nucleotide-binding proteins (G-proteins). Removal of caffeine is associated with an increase of intracellular [Ca2+] ([Ca2+]i) and the spatial and temporal characteristics of this Ca2+ signal are identical to those of the signal generated by the initial agonist stimulation. Caffeine is also a potent non-specific inhibitor of various cellular phosphodiesterases (PDE) and its inhibitory effect can be reproduced by other PDE inhibitors, chemically related (theophylline) or not (papaverine). Various protocols designed to increase the concentration of either of the major intracellular cyclic nucleotides [adenosine 3',5'-cyclic monophosphate (cAMP) and guanosine 3',5'-cyclic monophosphate (cGMP)] failed to reproduce the full extent of the caffeine inhibition: at maximal agonist concentration (1 microM ACh) increases of either cAMP or cGMP did not affect the Ca2+ signal, whereas at submaximal doses of agonist (0.1-0.3 microM ACh) they induced partial inhibition. Here we show that only the simultaneous increase of the cellular concentrations of both cyclic nucleotides (either simultaneous or sequential) are effective in mimicking the blocking effect of caffeine and other non-specific PDE inhibitors. These data indicate, thus, that, in addition to other independent intracellular effects, cAMP and cGMP can exert a co-ordinated inhibitory effect of the agonist-evoked Ca2+ signal in pancreatic acinar cells.
Camello
P J
PJ
Physiological Laboratory, Crown Street, PO Box 147, Liverpool L69 3BX, UK.
Petersen
O H
OH
Toescu
E C
EC
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D002110:Caffeine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000494:pharmacology*; D006152:Cyclic GMP / Q000494:pharmacology*; D004357:Drug Synergism; D066298:In Vitro Techniques; D015544:Inositol 1,4,5-Trisphosphate / Q000096:biosynthesis; D051379:Mice; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism; D010208:Papaverine / Q000494:pharmacology; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D015398:Signal Transduction; D013806:Theophylline / Q000494:pharmacology
D005576:Colforsin; D002110:Caffeine; D015544:Inositol 1,4,5-Trisphosphate; D013806:Theophylline; D010208:Papaverine; D000242:Cyclic AMP; D010727:Phosphoric Diester Hydrolases; D006152:Cyclic GMP; D000109:Acetylcholine; D002118:Calcium